G1 Therapeutics receives $33 million in Series B funding to develop effective treatments for cancer

An RTP-based pharmaceutical company with roots at the University of North Carolina at Chapel Hill has received $33 million in Series B venture capital funding to develop more effective and less toxic methods to treat patients with cancer.



from The Medical News http://ift.tt/16xI8nj